Targeting trafficking defects in long QT syndrome type 2: a phase 2 clinical study with patient-specific cellular validation

This study investigates whether lumacaftor (LUM) can effectively shorten the corrected QT interval (QTc) in patients with long QT syndrome type 2 (LQT2) caused by trafficking defects in the KCNH2 gene. The phase 2 clinical trial demonstrated that LUM significantly reduced QTc in patients, particularly those with higher baseline QTc values, and showed a correlation between clinical outcomes and cellular mechanisms in patient-specific cardiomyocytes. The findings suggest that LUM may serve as a promising mechanism-targeted therapy for LQT2, supporting the use of precision medicine in treating inherited arrhythmia syndromes.